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	Abstract 
Cancer immunotherapy is a new and promising option for cancer treatment. Unlike 
traditional chemo- and radiotherapy, immunotherapy actives host immune system to 
attack malignancies，and this potentially offers long-term protection from recurrence with 
less toxicity in comparison to conventional chemo- and radiation therapy. In adoptive 
CD8+ T cell therapy (ACT), large numbers of tumor-specific T cells are sourced from 
patients and expanded in vitro and infused back to patients. T cells can be expanded from 
naturally-induced tumor-specific CD8+ T cells isolated from tumor infiltrating 
lymphocytes (TIL) or genetically-modified autologous circulating CD8+ T cells. The 
engineered T cells expressed tumor-specific antigen receptors including chimeric antigen 
receptors (CARs) and T cell receptors (TCRs), prepared from cultured B and T cell clones, 
respectively. The most successful ACT, anti-CD19 chimeric antigen receptor T (CAR-T) 
cell therapy directed against B cell lymphoma, is already approved for use based on 
evidence of efficacy. Efficacy of solid tumors is not yet forthcoming. This review 
summarizes current technology developments using ACT in clinical trials. In this review, 
differences between various ACT approaches are discussed. Furthermore, resistance 
factors in the tumor microenvironment are also considered, as are immune related adverse 
effects, critical clinic monitoring parameters and potential mitigation approaches. 
Key word: adoptive cell therapy, immunotherapy, CAR T-cell therapy, TCR T-cell 
therapy 
	1. Introduction 1	
CD8+ T cells are the major immune cells to conduct immune surveillance to detect 2	
antigens derived from cancer cells and developing malignancies. CD8+ T cells are 3	
activated by TCR antigen recognition , followed by fast proliferation and differentiation 4	
into cytotoxic T lymphocytes (CTL), thus to eliminate cancer cells in the cell-cell contact 5	
manner. Lymphocytes are often found in the tumour lesion. The tumour infiltrating 6	
lymphocytes (TIL) contain immune cells specific to the tumour. The ex vivo cultured 7	
expanded cancer-specific CD8+ T cells can be infused back to the patient to control the 8	
tumour since 1988. This process is defined as adoptive cell-based therapy (ACT) since 9	
1988. Initial ACTs were performed using cells expanded from TIL (Figure 1A). More 10	
recently, gene-engineering technology enables the consistent generation of a large amount 11	
of cancer-specific T cells by transferring antigen receptor into in vitro activated T cells, 12	
such as TCR engineered T cells (TCR-T) and Chimeric Antigen Receptor T-cell (CAR-T), 13	
for cancer immunotherapy [1]. (Figure 1A and B). In comparison to TIL based ACT, 14	
TCR-T and CAR-T are much more consistent and robust process to produce large amount 15	
of cancer specific T cells. While the antigen receptors may derived from the TIL from 16	
certain patients, the use of the identified receptor can be extended to many patients with 17	
similar cancer.  TCR-T and CAR-T revolutionized the ACT, and have generated 18	
promising results in some cancer types, so far. However, some problems remain to be 19	
resolved for broad use of ACT in cancer clinic, such as safety, efficacy, and persistence. 20	
In this review, we summarized the progress and the challenges of ACT in clinical usage.    21	
2. The milestones of ACT to cancer 22	
	In ACT, autologous CD8+ T cells are derived from patients’ blood, tumor-associated 1	
lymph nodes or fresh tumor samples. The cancer specific T cells are expanded in vitro, 2	
and infused back into the patients. The tumor infiltrating lymphocytes (TILs), harvested 3	
from the liver and pulmonary metastases of a MCA-105 sarcoma patient, is the earliest 4	
ACT pioneered by Steven Rosenberg in 1988 [2]. Later, the multimeric peptide-MHC 5	
technology and antigen-dependent IFN-γ-secretion assay were used to isolate 6	
tumor-specific T cells from tumor sample and blood. Rosenberg and others firstly 7	
achieved cancer control by the adoptive transfer of autologous TILs after IL-2 8	
administration for melanoma with 60% objective response rate and the response range 9	
from 2 to 13 month. [3]. In 2002, lymphodepletion before TIL injection was realized to 10	
promote the transferred cell proliferation, functional maturation and be critical to cancer 11	
regression after ACT [4]. Nevertheless, a key process, in vitro expansion of 12	
tumor-specific T cells from TIL, remains to be technically challenging. In 2006, the first 13	
therapy using genetically modified CD8+ T cells with the TCR recognizing MART1 14	
melanoma antigen was reported to cause regression of metastatic melanoma in two 15	
patients but the transferred T cells engrafted well in all patients [5]. In 2011, TCR-T 16	
therapy specific a newly identified tumor antigen, NY-ESO-1, achieved success in 17	
treating synovial sarcoma with an objective resonse rate of 67% [6]. A distinctive type of 18	
antigen receptor, chimeric antigen receptor (CAR) targeting the B lymphocytes antigen 19	
CD19, was developed to treat advanced B cell lymphoma in 2010. CD19-specific CAR-T 20	
has shown great clinical efficacy in treating follicular lymphoma, large-cell lymphomas, 21	
chronic lymphocytic leukemia, and acute lymphocytic leukemia [7-10]. In 2014, the FDA 22	
	approved CD19-specific CAR-T therapy for relapsed/refractory ALL. In 2017, two 1	
commercial CAR-Ts were approved by the FDA for treating B-cell malignancies: 2	
Novartis's CAR-T (Kymriah) for children and young adults with refractory B-cell acute 3	
lymphoblastic leukemia (ALL), and Kite’s CAR-T (Yescarta) for adults with certain types 4	
of large B-cell lymphoma [11] (Figure 2). Until Dec. 2018, there are total of almost 600 5	
clinic trials with engineered CD8 T cells immunotherapy worldwide. USA and China are 6	
the top two countries in the numbers of clinical trials in CAR-T and TCR-T-cell therapy 7	
(Figure 3A). The clinical trials in China mainly located in 5 to 6 large cities with more 8	
prospective local economy(Figure 3B and C). According to unpublished data, the cost of 9	
30,000USD in China for every patient in the trial is cheaper than the cost of 50,000USD 10	
in US, except human resource cost. With the recent rapid progress in identification of 11	
tumor-specific antigen, CAR-T and TCR-T clinical trials are now actively targeting many 12	
hematological cancers and variety types of solid tumors. The CAR-T therapies 13	
predominantly target the hematological cancers, e.g. lymphoma and multiple myeloma, as 14	
anti CD19 CAR-Ts have shown their great efficacies in disease control, including disease 15	
free survival in some cases. TCR-T therapy are more targeting to solid tumors including 16	
Lung, liver, melanoma, head and neck cancer and lymphoma (Figure 4).   17	
2.1 TCR engineered T cells (TCR-T)   18	
TCR-Ts are genetically modified T cells expressing both α and β chain of a TCR 19	
specific to a tumor antigen. The source of TCR can be from a person carrying at least one 20	
same particular HLA allele as the patient to be treated or from humanized mice with a 21	
same HLA allele immunized with tumor antigens. Theoretically, the safest source of TCR 22	
	is the T cell repertoire from an HLA fully matched individual. Utilizing the autologous 1	
circulating lymphocytes as recipient cells, the TCR-Ts can be rapidly expanded through a 2	
stimulation using anti-CD3, anti-CD28 antibodies and IL-2 in vitro. TCR-Ts recognize the 3	
complex formed by tumor antigen-derived peptide and class I HLA. While the recognition 4	
is restricted by HLA type, TCR-T can recognize both cell surface and intracellular tumor 5	
antigen [12]. The first clinical trial conducted by Morgan and his partners shown that the 6	
infusion of MART-1 melanoma antigen-specific TCR-Ts led to objective regression in 7	
two patients with metastatic melanoma, in 2006 [5]. TCR-Ts targeting a number of tumor 8	
antigens are currently under clinical trials including MAGE-A3, MAGE-A4, GD2, 9	
mesothelin, gp100, MART1, CD19, AFP, CEA, NY-ESO-1, HER2, HPV, EBV, etc. 10	
NY-ESO-1 is the most promising target for many cancer immunotherapy [12-14] (table 11	
1).  12	
2.2 CAR-T 13	
CAR-Ts are constructed with an extracellular part of antibody-derived single-chain 14	
variable fragment (scFv) to T-cell receptor or co-receptors’ intracellular signaling 15	
domains, pioneered by Zelig Eshhar and Gideon Gross in 1989 [15]. CAR-Ts only 16	
recognize cell surface antigens but not restricted by HLA type. Types of antigens 17	
recognized by CAR-T can be extended to carbohydrates and glycolipids which often 18	
change in cancer cells [16]. Additional engineering of CAR to include intracellular 19	
signaling motifs from costimulatory molecules such as CD28, 4-1BB, OX40, and ICOS 20	
improves CAR-Ts proliferation and functions such as cancer cell killing activity and 21	
cytokine production [11]. Comparing to TCR-Ts, CAR-Ts are more universally applicable 22	
	to patients with various HLA types and to cancer type lacking HLA expression, which is a 1	
common strategy for cancer immune escape. The clinical trials of CAR-T involve the 2	
tumor targets of CD19, CD22, CD23, CD30, ROR-1, CAIX, PSMA, MUC1, FRz, 3	
meso-RNA, CEA, CD213a2, HER2, and yield encouraging results in treating multiple 4	
malignancies [17] (Table 2). 5	
 6	
3. The challenges and opportunities of adoptive CD8+ T cells immunotherapy 7	
3.1 The tumor-antigen specificity and mutation  8	
Genetically modified T cells carrying cloned tumor antigen receptors have been 9	
developed to generate a large quantity of tumor-specific CD8+ T cell for therapeutic use. 10	
Both viral vectors (adenovirus, retroviruses and lentiviruses) and non-viral systems 11	
(Sleeping Beauty [18] transposon system and CRISPR[19]) have been used to transfer 12	
antigen receptor into autologous CD8+ T cells in vitro. All cancers result from mutations 13	
in the genomic DNA sequence of cancer cells [20]. The data from the world’s largest and 14	
most comprehensive resource (TCGA database) for seeking the impact of somatic 15	
mutations in human cancers show that there are 2,002,811 coding region mutations, over 16	
six million noncoding mutations, 10,534 gene fusions, 61,299 genome rearrangements, 17	
695,504 abnormal copy number segments and 60,119,787 abnormal expression variants in 18	
1,029,547 tumor samples, involving almost all human genes [21]. Genetic mutations drive 19	
cancer development; but also benefit the cancer immunotherapy by providing neoantigens 20	
which are absent from the normal tissue. Accumulated results from clinical trials indicated 21	
that the tumor mutation burden (TMB) is a predictive biomarker for treatment response of 22	
	ACT and immune checkpoint inhibition therapy [22]. While immune checkpoint 1	
inhibitors (ICI) therapies generate a better outcome for patients with high TMB [23], 2	
patients with low TMB respond better to personalized CAR-T or TCR-T therapy [24]. 3	
Because a significant fraction of antigenic mutations in human tumors are not shared 4	
between patients,  most of the neoantigens are private antigens thus require personalized 5	
treatment. Combining whole-exome sequencing(WES) and bioinformatics analysis, 6	
personalized neoantigen-specific CAR-T cells were developed [25].  7	
Primary tumors can be genetically different from the associated metastatic lesions or 8	
local recurrences even for the very same patient. Cancer cells in the different region of the 9	
same primary tumor lesions are also genetically different [26]. Nearly 70% of all somatic 10	
mutations found on multiregional sequencing were geometrically heterogeneous and thus 11	
not detectable in every sequenced region [27]. Single cell sequencing technology revealed 12	
that cancer stem cells are also genetically heterogeneous, making ACT even more 13	
challenging [28]. 14	
Under the selection pressure of ACT, the cancer cells may evolve to escape the 15	
recognition by CD8+ T cells due to epitope mutation, leading to tumor recurrence. In 16	
2015, Stephan A. Grupp reported that most of the relapse of pediatric B-cell acute 17	
lymphoblastic leukemia (B-ALL) after the CAR-T-19 treatment is from the selection of 18	
CD19 variant with the mutated CAR-T-19 epitope [29]. Ideal neoantigens to target are 19	
those essential to the cellular transformation, cancer cell growth, and invasion with 20	
minimal normal tissue toxicity. Comparing to neoantigen CAR-T, neoantigen TCR-T 21	
relies on not only identification of neoantigen, but also the identification for HLA 22	
	restricted neoepitopes and their corresponding TCR [30, 31]. The key to success is that the 1	
T cell should carry an antigen receptor with high specificity to tumor neoantigen. The 2	
affinity between the antigen receptor and its antigen might also play an essential role in 3	
therapeutic efficacy. The TCR repertoire of naturally primed CD8+ T cells includes 4	
mostly TCRs with medium to low affinity, some of which are cross-reactive to 5	
autoantigens [32]. Nevertheless, lower affinity TCR may facilitate the priming of long 6	
lasting immune memory [33], including stem cells like memory T cells (Tscm). 7	
Mysteriously, natural TIL therapy seemed only succeeding in controlling melanoma and 8	
Hodgkin's disease but failed in other tumor types with identifiable tumor-associated 9	
antigens [34]. This could be a result of selective expanding of high affinity CTL clones 10	
under the in vitro culture condition. It is still unclear what is the optimal TCR affinity in 11	
determining the therapy outcome. As most of antibodies have much higher affinity than 12	
TCR, we speculate that CAR-T would be less favorable in treating solid tumor. The 13	
differences between TCR-T and CAR-T are listed in Table 3. 14	
 15	
3.2 The influence of immunosuppressive tumor microenvironment (TME) to ACT  16	
Multiple redundant cellular and molecular immune suppressive mechanisms in the 17	
TME cause CD8+ T cells dysfunction and exhaustion. Both cancer cells and host cells in 18	
the tumor play a role in inhibiting the anti-tumor immune response. Intratumor host 19	
accessory cells include cancer-associated fibroblast [35], endothelial cells [36], pericytes 20	
[37], immunosuppressive immune cells (Treg, tumor-associated macrophages, tolerogenic 21	
dendritic cells, Breg, myeloid-derived suppressor cells, mast cells) [38] [39]. These 22	
	accessory cells create immunosuppressive TME via pathways including 1) creating and 1	
reinforcing immune checkpoints[40]; 2) secreting immune suppressive cytokines e.g. 2	
transforming growth factor-beta (TGF-β) and IL10 [41]; 3) Physical elements(stiff ECM) 3	
[42]; 4) Chemical elements unfavorable to immune activation [43].  4	
Immune checkpoints are key regulatory points of the immune system to maintain 5	
immune tolerance to self. Activation of immune checkpoint(s) renders exhaustion of T 6	
cells by functional inactivation or physical deletion. Tumors exploit the immune 7	
checkpoints to evade immune destruction and cause tumor-specific T cell exhaustion. 8	
Most of the immune checkpoint molecules are cell surface receptors on activated T cells 9	
such as PD-1 [44], CTLA4 [45], and LAG3 [46] etc. and contain tyrosine-based inhibitory 10	
motifs (ITIMs) [47] as well as immunoreceptor tyrosine-based inhibitory switch motifs 11	
(ITSMs) [48]. The inhibition of PD-1/PD-L1 and CTLA-4 effectively blocked the T cell 12	
exhaustion and apoptosis, and facilitated the anti-tumor immune response, which was 13	
granted with Nobel Prize in 2018. FDA approved immune checkpoint inhibition therapy 14	
against melanoma, NSCLC, RCC, HNC, bladder cancer, HCC, urothelial cancer, cervical 15	
cancer and stomach cancer. Ligands for these immune checkpoint receptors are expressed 16	
in TME thus trigger the T cells exhaustion in TME. Immune checkpoints can be blocked 17	
using antibodies against immune checkpoint receptors to prevent the interaction between 18	
the receptors and their ligands [49]. IDO is a unique immune checkpoint protein by 19	
promoting tryptophan degradation via the kynurenine pathway and can be blocked using 20	
small molecule inhibitors. By converting tryptophan to kynurenine, IDO promotes 21	
immune suppression via two distinctive molecular mechanisms, 1) depletion of an 22	
	essential amino acid, tryptophan, to activate cellular stress pathways via GCN2 [50] and 2) 1	
generating downstream immune suppressive metabolites such as 3-hydroxyanthranillic 2	
acid [51] and xanthurenic acid [52]. Details of these mechanisms are extensively 3	
discussed in reviews [53]; thus we will not discuss this further due to the space limitation. 4	
Some immune checkpoint blockers are approved to be used in treating multiple cancer 5	
types, and combination therapies with ACT together are currently under clinic trials for 6	
various cancers, e.g. combination therapy of ACT with anti-CTLA4 (NCT02027935) or 7	
anti-PD1 (NCT02652455) [54, 55].  8	
Immune suppressive cytokines play important roles in immune tolerance to tumor. 9	
TGF-β, IL10 [56], VEGF [57], and prostaglandin E2 (PGE2) [58] are all recognized as 10	
major players in suppressing immunity using non-redundant mechanisms, including 11	
suppressing anti-tumor immunity of CTL, conventional dendritic cells, pDC, Natural 12	
killer cells, but supporting pro-tumor immunity of TAM, MDSC, Treg [59, 60].  13	
The stiff ECM together with tumor metabolic state create a physical acidic, hypoxia 14	
[61] local environment filled with polyamines produced via activated arginase pathway 15	
[62, 63]. This shelter the tumor antigen from immune surveillance, trap the cytotoxic T 16	
cells from infiltrating into tumor [64], and promote type 2 tumor-associated macrophage 17	
polarization and Treg activation [65] [66].  18	
The hostile metabolite situation in TME conducts a chemical barrier against ACT. The 19	
balance of nutrients and oxygen controls ACT destiny. The cancer cells won the 20	
competition of the consumption of glucose and amino acid against immune cells[67]. 21	
Besides of immune cells starving, HIF-1α in hypoxia induced glycolysis and lactate, 22	
	which both facilitate PD-L1 on tumor cells and stromal cells and PD-1 on CTL [68]. 1	
 2	
3.3 The short persistence of adoptively transferred tumor-specific T cells 3	
The longevity of ACT is an important factor for long-lasting tumor control effect. 4	
Current methodology uses initial potent activating stimuli, including CD3/CD28 5	
stimulation, IL-2 or allogeneic feeder cells, to produce T cells which can be transfected to 6	
carry tumor-specific CAR or TCR. This process generates a large number of functional 7	
CTLs with high level of perforin and granzyme. These CTLs are effective in controlling 8	
tumor in the short term while long term efficacy is variable due to complex 9	
immunosuppressive tumor microenvironment [69]. This is particularly problematic in 10	
treating solid tumors. It seems to be that the efficacy of initial tumor control by ACT is 11	
associated with high-affinity T cell engraftment, but this may not be true if a long-lasting 12	
antitumor T cell persistence is required. Low affinity T cells with the capability becoming 13	
stem memory T cells (Tscm) were reported to produce better and long lasting protective 14	
effects in mouse model of HCC [33]. Generating long lasting memory T cells including 15	
Tscm probably is the holy grail of ACT to reach the goal of long lasting tumor control or 16	
eradication. The number of memory T cells required for initial adoptive transfer therapy 17	
will be significantly lower than the current practice as memory cells can be primed in vivo 18	
using vaccine to regenerate CTL as needed. Current approaches to induce Tscm-like ACT 19	
include 1) Cytokines addition: IL-7, IL-15, IL-21 [70]; 2) using inhibitors for 20	
AKT ,mTORC and PI3K [71, 72]; 3) activation of NOTCH [73]; 4) Weak TCR signaling 21	
during activation [74]; 5）providing additional costimulation e.g. 4-1BB, ICOS [75]; 6) 22	
	altered metabolism status [76, 77]. These potentially persistent tumor specific T cells 1	
could control cancer and prevent recurrence for a long time [78, 79].  2	
 3	
3.4 The immune related toxicity of ACT therapy 4	
Toxicities from immune-related adverse effects (irAEs) were widely reported in 5	
many ACT cases including cytokine release syndrome (CRS), CAR-T-related 6	
encephalopathy syndrome (CRES), off-target/off-tumor toxicity. Unlike the immediate 7	
adverse effect of other chemotherapeutic drugs, the adverse effects of ACT happen weeks 8	
after T cells infusion and affect multiple organs [80].  9	
3.4.1 The CRS with uncontrollable inflammatory cytokines   10	
CRS is the most common life-threatening toxicity due to uncontrollable release of 11	
proinflammatory cytokines. CRS is characterized by high fever, skin rash, hypotension, 12	
hypoxia, cardiac dysfunction, kidney failure, electrolyte abnormalities and neurologic 13	
symptoms, even death [80]. The use of Glucocorticoids and/or antibodies blocking IL-1 14	
receptor (Anakinra) and IL-6 receptor (Tocilizumab), but not IFN-γ and TNF-α, could 15	
effectively reverse CRS [81] [82]. 16	
3.4.2 The on-target/off-tumor toxicity relates to antigens both on tumour and normal cells. 17	
The on-target/off-tumor toxicity is common in both CAR-T and TCR-T therapy. Many 18	
target antigens for cancer therapies are also present on normal cells, such CD19 on B cells, 19	
MART-1 on melanocytes, CAIX on biliary duct epithelium and CEA on normal 20	
gastrointestinal epithelial cells. Activated T cells targeting these antigens can recognize 21	
the same antigens expressed in normal tissues and cause damage. The CD19 CAR-T 22	
	therapy always induces transient or prolonged lack of B cells, resulting in adaptive 1	
immunoglobulin deficiency [83]. Severe toxicity was reported for multiple tissues damage 2	
including the skin, eyes, and ears in a late stage clinical trial enrolled 36 patients with 3	
metastatic melanoma received MART-1 or gp100-specific TCR-T cells[84, 85].  4	
3.4.3 The cross-reactive off-target/off-tumor toxicities  5	
Off-target/off-tumor toxicities are caused by cross-reactivity of antigen receptor to 6	
autoantigens not associated with tumors. Tumor antigen MAGE-A3-specific TCR-T 7	
reacts with a few known autoantigens including MAGE-A12 expressed in brain and titin 8	
expressed in cardiac muscle. An early-stage clinical trial using MAGE-A3-specific 9	
TCR-T resulted in two death from total nine patients due to severe neurological toxicity 10	
and two cardiovascular-related deaths in another clinical trial [86, 87]. 11	
3.4.4 The neurotoxicity of ACT 12	
The irAEs related neurotoxicity including confusion, delirium, expressive aphasia, 13	
obtundation, myoclonus, and seizure has been reported in patients after receiving ACT. It 14	
is unclear how the tumor targeting immune response causes the neurological toxicities 15	
because the central nervous system (CNS) is usually well isolated from peripheral tissue 16	
by the tightly controlled blood-brain barrier. The severity of CRS, on target/off-tumor and 17	
off-target/off-tumor, may together contribute to the neurotoxicity [88]. It is worthwhile to 18	
mention that elevated kynurenine production by inducing indoleamine 2, 3 dioxygenase 19	
(IDO) during infection led to neuropathic pain [89]. Same mechanisms probably 20	
contribute to irAEs, such as kynurenine production being often increased in cancer patient 21	
and further enhanced by therapy [90]. CAR-T-related encephalopathy syndrome (CRES) 22	
	is the most severe neurological syndrome and its development is critically dependent on 1	
monocytes-derived IL-1 and IL-6. Neutralizing these two cytokines reversed CRES 2	
effectively [81]. The inflammatory cytokines may activate endothelial cells of the 3	
blood-brain barrier and disrupt the barrier integrity, and endothelial cell activation in the 4	
central nervous system might drive the CAR-T therapy associated neurotoxicity [91].  5	
 6	
3.4.5 The prevention and treatment for the irAEs 7	
Efforts have been made to improve the safety of ACT tumor therapy. The first line 8	
drugs against irAEs are glucocorticoid and dexamethasone, with supportive care [92]. 9	
Some antagonists to inflammatory cytokines also decrease the toxicity [43]. Recently, 10	
self-amplifying catecholamine loop was found as a self-amplifier of CRS, and inhibiting 11	
key steps in the catecholamine synthesis pathway with metyrosine effectively reduced the 12	
CRS toxicity in mouse [93]. 13	
The on-demand cell destruction of engineered T cells is designed with co-transfer of 14	
suicide genes together with antigen receptors. Commonly used suicide genes include 15	
herpes simplex virus thymidine kinase (HSV-TK), inducible caspase-9 (iCasp9). Insertion 16	
of HSV-TK increases the T cells’ susceptibility to ganciclovir. The strategy was 17	
developed to control graft-versus-host disease (GVHD) after allogeneic transplantation or 18	
ease immunologic response after CTLs infuse into immune-deficient hosts. iCasp9 is a 19	
genetically engineered human caspase-9 protein with the endogenous activation domain 20	
replaced by a controllable dimerization domain from human FK506-binding protein. A 21	
mutation (F36V) was introduced to allow specific binding to a bio-inert chemical 22	
	induction of dimerization (CID) drug, AP1903. Upon binding to AP1903, iCasp9 1	
activates and leads to quick apoptotic cell death of CTLs [18, 94]. Introducing these 2	
suicide genes made the CAR-T and TCR-T more controllable, but remains to be 3	
challenging in clinic. HSV-TK is immunogenic, and the induction of cell death is a slow 4	
process [95]. Thus, it is hard to reverse strong acute CRS toxicities, although HSV-TK 5	
renders the cells sensitive to gancyclovir [96]. iCasp9 is activated by a CID that is not 6	
widely available and extensively tested. The efficacy and safety of the broad usage of 7	
these suicide genes in cancer ACT need to be further evaluated.  8	
 9	
Conclusion 10	
After decades of research, the power of CD8+ T cells has finally been wielded in our 11	
battle against cancer. Clinical application of ACT in tumor therapy starts to achieve 12	
encouraging results. Recent technology advances such as bioinformatics, deep sequencing 13	
in single-cell level, structure biology, and genetic-manipulation etc. continuously supply 14	
new weapons to the old foot soldier CD8+ T cells. Nevertheless, many challenges remain 15	
to be solved to overcome the scientific (Figure 5), and economic (Figure 3B, C) barriers, 16	
with the global high price tag of Kymriah (475,000 USD in US, 307,000 USD in Japan, 17	
373,000 USD in UK), to establish a universal and viable therapeutic platform.  18	
 19	
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TMB: tumor mutation burden  21	
WES: whole-exome sequencing 22	
irAEs: immune-related adverse effects 23	
CRS: cytokine release syndrome 24	
CRES: CAR-T-related encephalopathy syndrome 25	
IDO: indoleamine 2, 3 dioxygenase 26	
HSV-TK: herpes simplex virus thymidine kinase 27	
iCasp9:inducible caspase-9  28	
GVHD: graft-versus-host disease 29	
CID: chemical induction of dimerization 30	
TME: tumor microenvironment  31	
ECM: extracellular matrix 32	
PD-1: Programmed cell death protein 1 33	
CTLA-4: cytotoxic T-lymphocyte-associated protein 4 34	
LAG-3: Lymphocyte-activation gene 3 35	
ITIM: tyrosine-based inhibitory motifs  36	
ITSM: immunoreceptor tyrosine-based inhibitory switch motif (ITSMs) 37	
GCN2: general control nonderepressible 2 38	
VEGF: Vascular endothelial growth factor 39	
Tscm: stem-like memory T cells 40	
PI3K: phosphatidylinositol 3-kinase  41	
mTORC: The mammalian target of rapamycin 42	
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	  1	
	Figure 1:	 Adoptive cell therapy is currently represented by three general 1	
approaches. TILs are derived form surgical excision of tumor, and TCR- and 2	
CAR-modified T cells are produced from peripheral blood lymphocytes with 3	
genetic engineered antigen receptors. A. The universal procedure of ACT. B. The 4	
different binding pattern of TCR-T and CAR-T. 5	
 6	
 7	
Figure 2: A brief history of ACT. Figure depicted key events in the development 8	
of ACT in treating cancer from the year 1988 to 2018.  Important milestones 9	
include 1) initial pioneer work by Steven Rosenberg using TIL to treat metastatic 10	
sarcoma; 2) transfer of genetically modified T cells expression cancer cell specific 11	
antigen receptor since 2006; 3) FDA first approval of CAR-T use in clinic in 2014.  	12	
	13	
	14	
Figure 3: The geometric distribution of clinical trials of CAR-T and TCR-T. 15	
Regional economic status strongly influences the access to ACT in cancer clinic. 16	
(A). The global distribution of clinical trials with CAR-T and TCR-T cells. United 17	
States and China are the top 2 countries of clinic trials of engineered T cells 18	
(CAR-T and TCR-T), take almost 90% of the total number of trials worldwide, 19	
suggesting that strong economic support is a major factor influencing the patient’s 20	
access to ACT therapy. Even within China, current CAR-T and TCR-T trials are 21	
preferentially located in few cities with better economic environment (B and C). 22	
Among them, three super-sized cities Beijing, Shanghai and Guangzhou are the 23	
most advanced cities in clinic trials of engineered T cells, together taking about 50% 24	
of total number of trial in China. Innovations aiming for cost cutting for the ACT 25	
therapy will be a major challenge for its clinic application. 26	
 27	
 28	
Figure 4. The composition of cancer types in CAR-T and TCR-T trials. The 29	
hematological malignancies (lymphoma and multiple myeloma) are the major 30	
cancer types for ACT therapy trials. A diversified spectrum of solid tumors is also 31	
been tested, among which pancreatic cancer and breast cancer are the top three 32	
trials in CAR-T. TCR-T therapy has been seen with better efficacy in treating solid 33	
tumors, thus more diversified cancer types have been trialed for TCR-Therapy in 34	
comparison to CAR-T therapy.  Major cancer types including lymphoma, 35	
thoracic cancer, cervical cancer, head and neck cancer and colorectal cancer  36	
 37	
Figure 5:	Optimization strategy for successful ACT therapy in clinic. Four major 38	
factors are to be improved when apply ACT therapy in cancer clinic. (1) Tumor 39	
antigen mutation may not always fit an available generic antigen receptor.  40	
Development of personalized ACT by identifying tumor neo-antigens and their 41	
specific antigen receptors using Nextgen sequencing plus bioinformatics analysis 42	
will better tailor the therapy from individual to serve broader patient population. 43	
More efficient targeted gene delivery technologies such as Crispr/Cas9 gene 44	
	editing will accelerate service to bypass long process of viral vector production, 1	
increase both safety and efficiency. (2) During tumor progression, cancer cells 2	
change normal developmental procedure to setup a supportive 3	
butimmunosuppressive tumor microenvironment (TME) comprised of immune 4	
cells, fibroblasts, pericytes, and endothelial cells, often covered within 5	
extracellular matrix (ECM), with abnormality of metabolism and hypoxia. Short 6	
persistence of transferred immune cells and immune suppressive TME pose major 7	
threats for successful therapy and long lasting protection. Combination therapies to 8	
include ICI agents and/or blocking antibodies against immune suppressive 9	
cytokines are expected to greatly improve ACT therapies. Selection of long lasting 10	
memory T cells to carried the cancer targeting antigen receptor are expected to 11	
offer long term protection as well as reducing cell number required for initial 12	
transfer.   (3) ACT therapy toxicities, sometime lethal adverse effects, are 13	
already well known. Efforts have been taken to develop cancer targeting immune 14	
cells with sophisticated genetically engineer including safe-keep mechanisms, but 15	
this approach is yet to be demonstrated successful. There is a strong need to 16	
develop a standardized guideline to recognize and treat ACT therapy adverse 17	
effects. Most of acute symptoms related ACT therapy toxicities are treatable if 18	
recognized on time. Long-term consequences, in particular neurotoxicity are yet to 19	
be understood. TME: Tumor microenvironment. ICP: Immune Checkpoint. ISC: 20	
Immunosuppressive cytokines. ECM:. HMS: Hostile Metabolic State. CRS: 21	
Cytokine release syndrome 22	
 23	
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